inotuzumab ozogamicin

(redirected from CMC-544)
Also found in: Wikipedia.

inotuzumab ozogamicin

A humanised CD22 linked to calicheamicin, which is being studied as a possible therapy for acute lymphoblastic leukaemia. Early data suggests that it can induce the desirable apoptosis of malignant cells at lower doses than those required for the CD33 immunotoxin gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia,
References in periodicals archive ?
15 Inotuzumab Ozogamicin / CMC-544 Market (USD Million), Long Term Forecast: 2018-2024 (Base Scenario) Figure 5.
AG-858, Aldesleukin , Alemtuzumab, AP23573, Apolizumab, Arsenic trioxide, Atra, Avastin, BAY 43-9006, Bevacizumab, BiovaxID , Bortezomib , CEP-701, Ceplene, Clofarabine, Cloretazine, CMC-544 , Decitabine, Enzastaurin , Epratuzumab, FavId , FK228, Flavopiridol, Gemtuzumab, Genasense, Gvax, IDEC-114 , Imatinib, Marqibo, MyVax, Nelarabine , OSI-461, Pixantrone , PKC412, PTK787, Rituximab, SGN-30, SGN-40 , SU5416, Temsirolimus , Troxacitabine, Valspodar, VELCADE, Xcytrin, Zanolimumab, Zarnestra etc.
Aldesleukin , Apolizumab, Arsenic trioxide, Bevacizumab, BiovaxID, Bortezomib, CMC-544 , Enzastaurin , Epratuzumab, FavId , Flavopiridol, Genasense , IDEC-114 , Marqibo, MyVax, Nelarabine , Pixantrone, SGN-30, SGN-40, Temsirolimus, Zanolimumab.
Inotuzumab Ozogamicin / CMC-544 Sales Forecast, 2013-2018 4.
4-1BBL, 506U78, Actimmune, Ad-IFNg, AlloMune, AMD-3100, Aplidin, ASIbcl, Atragen, Avastin, BCX1777, B-E8, Beta LT, Bexxar, Caelyx, Calsed, Campath, Clofarabine, CMC-544, CpG-7909, Depocyte, Edodekin Alpha, Elsamitrucin, FAVID, Fludara, FR-901228, Ganite, GEMZAR, GENASENSE, GRN163, GTI-2040, GTOP-99, hA20, HMR1275, HSPPC-96, Hu1D10, hum291, HuMax, IDEC-114, IDEC-152, IDIOVAX, Intron A, INX-3280, ISF-154, KiroMAb, LY317615, Lymphocide, Lymphorad131, MDX-060, MGV, Midostaurin, MT103, NIPENT, NOVATRONE, Oncolym, OncoTCS, Ontak, Orathecin Rubitecan, Parlodel, PEGIntron, Porleukin, Pretarget Lymphoma, PRO64553, Product R, Prothecan, Remitogen, Rituxan, SGN-30, SGN-35, T-900607, TH9402, Thalidomid, Trap, TRISENOX, UCN-01, VAXID, VB2-011, VEGF Trap, VELCADE, Zevalin
9 Inotuzumab Ozogamicin / CMC-544 Market (USD MM), Long Term Forecast: 2019-2023 (Base Scenario)
Antitumor Efficacy of a Combination of CMC-544 (Inotuzumab Ozogamicin), a CD22-Targeted Cytotoxic Immunoconjugate of Calicheamicin, and Rituximab against Non-Hodgkin's B-Cell Lymphoma.
CMC-544 CMC-544 is an anti-CD22 antibody linked to calicheamicin, a potent cytoxic drug, using technology developed for the FDA-approved drug Mylotarg.
Among novel targeted cytotoxic antibiotics are biotinylated CBI-bearing CC-1065 analogs, bispecific monoclonal antibodies (MAb), cytotoxic peptide conjugates targeted to their receptors on tumors (AN-215, AN-238, D-26232, C-terminal gastrin heptapeptide-targeted cytotoxics), CMC-544, Davanat-2, HPMA-HA-DOX, immunoliposomes (CA15-3 targeting, anti-HER2/doxorubicin immunoliposomes, EGFr-targeted/epirubicin immunoliposomes, and MCC-465), SGN-15, and vitamin-mediated targeted delivery.